Context Therapeutics Inc.

For the period ended Mar 31, 2026. Filed May 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 6, 2026

CNTX$0.20+3.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

	March 31, 2026	December 31, 2025
	(Unaudited)	(Note 3)
Assets
Current assets:
Cash and cash equivalents	$54,528,596	$65,995,228
Prepaid expenses and other current assets	3,988,220	2,358,474
Total current assets	58,516,816	68,353,702
Property and equipment, net	62,227	29,656
Operating lease right-of-use lease asset	280,050	110,410
Total assets	$58,859,093	$68,493,768
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$2,465,729	$2,532,887
Accrued expenses and other current liabilities	3,908,565	5,375,090
Operating lease liability - current	160,055	112,064
Total current liabilities	6,534,349	8,020,041
Operating lease liability - non-current	122,369	—
Total liabilities	6,656,718	8,020,041
Commitments and contingencies (Note 8)
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding	—	—
Common stock, $0.001 par value; 200,000,000 shares authorized at March 31, 2026 and December 31, 2025; 91,879,177 shares issued and outstanding at March 31, 2026 and December 31, 2025	91,879	91,879
Additional paid-in capital	191,694,377	191,285,157
Accumulated deficit	(139,583,881)	(130,903,309)
Total stockholders' equity	52,202,375	60,473,727
Total liabilities and stockholders' equity	$58,859,093	$68,493,768

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.